保妇康栓联合重组人干扰素治疗高危型宫颈人乳头瘤病毒持续感染的临床研究  

A clinical study on treating high-risk HPV persistent infection with the Baofukang suppository plus rh IFN

作　　者：唐梅艳[1] 唐冬艳 李俊菲[3] 

机构地区：[1]湖南省湘南学院妇产科学教研室,湖南郴州423000 [2]广东深圳石岩镇人民医院,广东深圳518000 [3]湖南省湘南学院附属医院,湖南郴州423000

出　　处：《中医临床研究》2018年第4期72-74,共3页Clinical Journal Of Chinese Medicine

基　　金：湖南省教育厅科研项目湘财教指[2015]54号15C1283

摘　　要：目的:探究保妇康栓联合重组人干扰素治疗高危型宫颈人乳头瘤病毒持续感染的临床疗效。方法:本研究选取2016年2月-2017年1月于我院妇科进行诊断及治疗的HPV持续感染患者60例,按照随机数字表法分为3组(对照组A,对照组B,观察组),每组20例,三组患者均给予相同的基础治疗,如常规阴道清洁及分泌物擦拭等,对照组A患者给予保妇康栓治疗,对照组B患者给予重组人干扰素α-2b凝胶治疗,观察组将对照组A和对照组B的治疗方法联合应用,比较三组患者总有效率、异常分泌物持续时间、HPV转阴时间及不良反应发生情况。结果:对照组A患者总有效率为70%,对照组B患者总有效率为75%,观察组患者总有效率为95%,观察组明显高于对照组A和对照组B,差异具有统计学意义(P<0.05);观察组患者异常分泌物持续时间及HPV转阴时间均低于对照组A和对照组B,差异均具有统计学意义(P<0.05);对照组A、对照组B和观察组患者发生不良反应的发生率分别为20%、15%、20%,差异无统计学意义(P>0.05)。结论:保妇康栓联合重组人干扰素治疗高危型宫颈人乳头瘤病毒持续感染疗效确切,且联合用药安全性较高。Objective:To study efficacy of the Baofukang suppository(保妇康栓)plus rhIFN on high-risk HPV persistent infection.Methods:60 cases were divided into 3 groups,20 cases in each group.All patients were given conventional treatment.The control A group took the Baofukang suppository.The control B group took rhIFN.The observation group received the Baofukang suppository plus rhIFN.Results:The total efficiency was 70%in the control A group,75%in the control B group,and 95%in the observation group.The total efficiency was best in the observation group(P<0.05).The duration of abnormal secretions and the time of HPV negative conversion in the observation group were shorter than those in the control A and B groups(P<0.05).The incidence of adverse reactions were 20%,15%and 20%in the control A group,control B group and observation group respectively,with no significant difference(P>0.05).Conclusion:The Baofukang suppository plus rhIFN on high-risk HPV persistent infection was effective,with safety.

关 键 词：人乳头瘤病毒 保妇康栓 重组人干扰素 持续感染 

分 类 号：R373.9[医药卫生—病原生物学]